Ardelyx Q2 revenue $97.7M (+33%), raises IBSRELA guidance; CFO to depart

ARDELYX, INC.

2025-Q2 EPS reported -$0.25 revenue$171,776,000

Q2 total revenue $97.7M (+33% YoY); IBSRELA net sales $65M (+84% YoY); XPHOZAH net sales $25M (-33% YoY).
Raised FY2025 IBSRELA U.S. net sales revenue outlook to $250-260M from prior guidance.
Net loss $19.1M ($0.08/sh) vs $16.5M ($0.07) YoY; cash & investments $238.5M at June 30, 2025.
CFO Justin Renz to transition out by Dec 31, 2025 or upon new CFO start; transition agreement signed.
Drew $48.7M net from SLR term loan; option to draw additional $100M in two tranches.

item 2.02 item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ARDELYX, INC.: Board adopted Second Amended and Restated Bylaws updating procedural and disclosure requirements for shareholder nominations and proposals, quorum provisions, stockholder list requirements, and adding a forum selection provision (effective 2025-08-01).

Change: bylaw amendment
Effective: 2025-08-01

Exact text from the filing

On August 1, 2025, the Board of Directors (the “Board”) of the Company approved and adopted the Company’s Second Amended and Restated Bylaws (as amended and restated, the “Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-25-037441

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.